ReviewJournal of clinical oncology : official journal of the American Society of Clinical Oncology2021
Immunotherapy in Older Adults With Cancer.
Review in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Update.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Guideline
- Preliminary exploration of the optimal timing of chemoimmunotherapy combined with radiotherapy for oligometastatic esophageal squamous cell carcinoma and analysis of prognostic factors: a multicenter retrospective study.Frontiers in oncology · 2026Article
- Real-life follow-up after discontinuation of anti-PD1 therapy for complete-response cutaneous squamous cell carcinoma in patients over 75 years of age.The oncologist · 2025Article
- Co-targeting CDK4/6 enhances anti-cancer activity and alleviates immune-related adverse events of anti-PD-1 antibody for breast cancer.Cell reports. Medicine · 2025Article
- Review
- Association between opioid use and survival in advanced non small cell lung cancer patients treated with immune checkpoint inhibitors.Scientific reports · 2025Article
- Understanding frailty and the role of patient-centered care for older adults with gynecologic cancer.Gynecologic oncology · 2025Review
- Real-world data on immunotherapy combined with chemotherapy in elderly patients with extensive-stage small cell lung cancer.BMC cancer · 2025Article
- Early-Stage Renal Cell Carcinoma: Who Needs Adjuvant Therapy?Biomedicines · 2025Review
- Review
- Older adults with cancer and common comorbidities-challenges and opportunities in improving their cancer treatment outcomes.Journal of the National Cancer Institute · 2024Article
- Toxicity of Cancer Immunotherapies in Older Patients: Does Age Make a Difference?Drugs & aging · 2024Review
- A Review of Immunotherapy in Non-Small-Cell Lung Cancer.Current oncology (Toronto, Ont.) · 2024Review
- Aging and cancer.Molecular cancer · 2024Review
- NK cell transfer overcomes resistance to PD-(L)1 therapy in aged mice.Experimental hematology & oncology · 2024Article
- Long-term survival after anti-PD-1 discontinuation in advanced cutaneous squamous cell carcinoma (cSCC): a proof of concept of benefit of concomitant cemiplimab and radiotherapy.Cancer immunology, immunotherapy : CII · 2024Article
- Clinical Characteristics, Treatment Patterns, and Outcomes of Patients With Locally Advanced/Metastatic Hepatocellular Carcinoma Treated at the Veterans Health Administration.The oncologist · 2024Article
- Immune Checkpoint Inhibitors in Geriatric Oncology.Current oncology reports · 2024Review
- Effectiveness and Safety of Immune Checkpoint Inhibitors in Older Cancer Patients.Journal of personalized medicine · 2024Article
- PD-1 inhibitor sintilimab treated patients with metastatic triple-negative breast cancer.Frontiers in cell and developmental biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 3 countries.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.